Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission

Sung Chao Chu, Tso Fu Wang, Yu Chieh Su, Ruey Ho Kao, Yi Feng Wu, Dian Kun Li, Szu Chin Li, Chi Cheng Li, Denise A. Wells, Michael R. Loken

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

Fifty-one consecutive non-M3 acute myeloid leukemia (AML) patients who had achieved morphologic complete remission (mCR) after induction chemotherapy were enrolled in the present study. Three characteristics of bone marrow (BM) composition analyzed by flow cytometry were combined to determine the prognostic impact. A standardized panel of reagents was used to detect residual disease of aberrant myeloid progenitor cells (RD), identify neutrophils/monocytes with dysregulated immunophenotype (dysregulated neutro/mono) and quantify the appearance of CD34+ B-progenitor-related cluster (hematogones) simultaneously in post-induction BM of adult AML patients. Patients who had detectable RD ≥0.2 % exhibited significantly lower median leukemia-free survival (LFS) than those who did not (13.5 vs. 48.0 months; P = 0.042). Dysregulated neutro/mono abnormalities assessed by this flow cytometric scoring system (FCSS ≥2) predicted shorter LFS (8.0 vs. 39.0 months; P = 0.008). While B-progenitor-related cluster size ≥5 % predicted improved outcome, with longer LFS (not reached vs. 13.5 months; P = 0.023) and better overall survival (not reached vs. 24.0 months; P = 0.027). The proposed RD/dysregulated neutro/mono/hematogones score showed a new risk groups with different LFS in the overall patients (P = 0.0006) as well as in the subgroup of intermediate cytogenetic risk (P = 0.001). The RD/dysregulated neutro/mono/hematogones score assessed by flow cytometry for adult AML in mCR may offer a rapid and practical risk assessment providing better refinement in risk-adapted management after induction chemotherapy.
原文英語
頁(從 - 到)296-304
頁數9
期刊International Journal of Hematology
99
發行號3
DOIs
出版狀態已發佈 - 一月 1 2014
對外發佈Yes

指紋

Acute Myeloid Leukemia
Monocytes
Neutrophils
Leukemia
Survival
Induction Chemotherapy
Flow Cytometry
Bone Marrow
Myeloid Progenitor Cells
Remission Induction
Risk Management
Cytogenetics

ASJC Scopus subject areas

  • Hematology

引用此文

Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission. / Chu, Sung Chao; Wang, Tso Fu; Su, Yu Chieh; Kao, Ruey Ho; Wu, Yi Feng; Li, Dian Kun; Li, Szu Chin; Li, Chi Cheng; Wells, Denise A.; Loken, Michael R.

於: International Journal of Hematology, 卷 99, 編號 3, 01.01.2014, p. 296-304.

研究成果: 雜誌貢獻文章

Chu, Sung Chao ; Wang, Tso Fu ; Su, Yu Chieh ; Kao, Ruey Ho ; Wu, Yi Feng ; Li, Dian Kun ; Li, Szu Chin ; Li, Chi Cheng ; Wells, Denise A. ; Loken, Michael R. / Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission. 於: International Journal of Hematology. 2014 ; 卷 99, 編號 3. 頁 296-304.
@article{31b74f7315d64d948d5be56ccdac4fdd,
title = "Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission",
abstract = "Fifty-one consecutive non-M3 acute myeloid leukemia (AML) patients who had achieved morphologic complete remission (mCR) after induction chemotherapy were enrolled in the present study. Three characteristics of bone marrow (BM) composition analyzed by flow cytometry were combined to determine the prognostic impact. A standardized panel of reagents was used to detect residual disease of aberrant myeloid progenitor cells (RD), identify neutrophils/monocytes with dysregulated immunophenotype (dysregulated neutro/mono) and quantify the appearance of CD34+ B-progenitor-related cluster (hematogones) simultaneously in post-induction BM of adult AML patients. Patients who had detectable RD ≥0.2 {\%} exhibited significantly lower median leukemia-free survival (LFS) than those who did not (13.5 vs. 48.0 months; P = 0.042). Dysregulated neutro/mono abnormalities assessed by this flow cytometric scoring system (FCSS ≥2) predicted shorter LFS (8.0 vs. 39.0 months; P = 0.008). While B-progenitor-related cluster size ≥5 {\%} predicted improved outcome, with longer LFS (not reached vs. 13.5 months; P = 0.023) and better overall survival (not reached vs. 24.0 months; P = 0.027). The proposed RD/dysregulated neutro/mono/hematogones score showed a new risk groups with different LFS in the overall patients (P = 0.0006) as well as in the subgroup of intermediate cytogenetic risk (P = 0.001). The RD/dysregulated neutro/mono/hematogones score assessed by flow cytometry for adult AML in mCR may offer a rapid and practical risk assessment providing better refinement in risk-adapted management after induction chemotherapy.",
keywords = "Acute myeloid leukemia, Flow cytometry, Hematogones, Residual disease",
author = "Chu, {Sung Chao} and Wang, {Tso Fu} and Su, {Yu Chieh} and Kao, {Ruey Ho} and Wu, {Yi Feng} and Li, {Dian Kun} and Li, {Szu Chin} and Li, {Chi Cheng} and Wells, {Denise A.} and Loken, {Michael R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12185-014-1525-y",
language = "English",
volume = "99",
pages = "296--304",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission

AU - Chu, Sung Chao

AU - Wang, Tso Fu

AU - Su, Yu Chieh

AU - Kao, Ruey Ho

AU - Wu, Yi Feng

AU - Li, Dian Kun

AU - Li, Szu Chin

AU - Li, Chi Cheng

AU - Wells, Denise A.

AU - Loken, Michael R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Fifty-one consecutive non-M3 acute myeloid leukemia (AML) patients who had achieved morphologic complete remission (mCR) after induction chemotherapy were enrolled in the present study. Three characteristics of bone marrow (BM) composition analyzed by flow cytometry were combined to determine the prognostic impact. A standardized panel of reagents was used to detect residual disease of aberrant myeloid progenitor cells (RD), identify neutrophils/monocytes with dysregulated immunophenotype (dysregulated neutro/mono) and quantify the appearance of CD34+ B-progenitor-related cluster (hematogones) simultaneously in post-induction BM of adult AML patients. Patients who had detectable RD ≥0.2 % exhibited significantly lower median leukemia-free survival (LFS) than those who did not (13.5 vs. 48.0 months; P = 0.042). Dysregulated neutro/mono abnormalities assessed by this flow cytometric scoring system (FCSS ≥2) predicted shorter LFS (8.0 vs. 39.0 months; P = 0.008). While B-progenitor-related cluster size ≥5 % predicted improved outcome, with longer LFS (not reached vs. 13.5 months; P = 0.023) and better overall survival (not reached vs. 24.0 months; P = 0.027). The proposed RD/dysregulated neutro/mono/hematogones score showed a new risk groups with different LFS in the overall patients (P = 0.0006) as well as in the subgroup of intermediate cytogenetic risk (P = 0.001). The RD/dysregulated neutro/mono/hematogones score assessed by flow cytometry for adult AML in mCR may offer a rapid and practical risk assessment providing better refinement in risk-adapted management after induction chemotherapy.

AB - Fifty-one consecutive non-M3 acute myeloid leukemia (AML) patients who had achieved morphologic complete remission (mCR) after induction chemotherapy were enrolled in the present study. Three characteristics of bone marrow (BM) composition analyzed by flow cytometry were combined to determine the prognostic impact. A standardized panel of reagents was used to detect residual disease of aberrant myeloid progenitor cells (RD), identify neutrophils/monocytes with dysregulated immunophenotype (dysregulated neutro/mono) and quantify the appearance of CD34+ B-progenitor-related cluster (hematogones) simultaneously in post-induction BM of adult AML patients. Patients who had detectable RD ≥0.2 % exhibited significantly lower median leukemia-free survival (LFS) than those who did not (13.5 vs. 48.0 months; P = 0.042). Dysregulated neutro/mono abnormalities assessed by this flow cytometric scoring system (FCSS ≥2) predicted shorter LFS (8.0 vs. 39.0 months; P = 0.008). While B-progenitor-related cluster size ≥5 % predicted improved outcome, with longer LFS (not reached vs. 13.5 months; P = 0.023) and better overall survival (not reached vs. 24.0 months; P = 0.027). The proposed RD/dysregulated neutro/mono/hematogones score showed a new risk groups with different LFS in the overall patients (P = 0.0006) as well as in the subgroup of intermediate cytogenetic risk (P = 0.001). The RD/dysregulated neutro/mono/hematogones score assessed by flow cytometry for adult AML in mCR may offer a rapid and practical risk assessment providing better refinement in risk-adapted management after induction chemotherapy.

KW - Acute myeloid leukemia

KW - Flow cytometry

KW - Hematogones

KW - Residual disease

UR - http://www.scopus.com/inward/record.url?scp=84899455356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899455356&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1525-y

DO - 10.1007/s12185-014-1525-y

M3 - Article

VL - 99

SP - 296

EP - 304

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -